For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

The tumor microenvironment (TME) chiefly consists of tumor cells and tumor-infiltrating
immune cells admixed with the stromal component. A recent clinical trial has shown that the …

Abstract Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade
has been approved as the standard-of-care for the treatment of non-small cell lung cancer …

SMARCA4, also known as transcription activator, is an ATP-dependent catalytic subunit of
SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-remodeling complexes that …

Introduction Acquired resistance to TKI is an important unmet need in the management of
EGFR mutated lung cancer. Recent clinical trial IMPower150 suggested that combination …

Objective Progress in neoadjuvant therapy for resectable nonsmall cell lung cancer (NSCLC
1) has been stagnant. There have been great achievements in immunotherapy for advanced …

Background We indirectly compared the effects of immune checkpoint inhibitors alone (ICI)
and ICI-combined chemotherapy (chemo-ICI) in patients with non-small cell lung cancer …

Patients with locally advanced esophageal squamous cell carcinoma (ESCC) show poor
survival after concurrent chemoradiotherapy. This study investigated the safety and …